Baidu
map

2015英国2型糖尿病指南[讨论稿]:降压与抗血小板治疗

2015-03-04 郭艺芳 郭艺芳微博

河北省人民医院  郭艺芳英国国家健康与保健优化研究所(NICE)将于2015年9月颁布新一版成人2型糖尿病管理指南,现已公布新指南的初稿征集意见。新版指南重新梳理了现有研究结论,在2009年版指南基础上进行了修订。初稿公布后,其关于降糖治疗流程的建议迅即引起多位糖尿病专家的强烈质疑(特别是将瑞格列奈与吡格列酮作为二甲双胍之后首选的二线降糖药)。关于其他心血管危险因素的控制,新版指南未纳入

河北省人民医院  郭艺芳

英国国家健康与保健优化研究所(NICE)将于2015年9月颁布新一版成人2型糖尿病管理指南,现已公布新指南的初稿征集意见。新版指南重新梳理了现有研究结论,在2009年版指南基础上进行了修订。初稿公布后,其关于降糖治疗流程的建议迅即引起多位糖尿病专家的强烈质疑(特别是将瑞格列奈与吡格列酮作为二甲双胍之后首选的二线降糖药)。关于其他心血管危险因素的控制,新版指南未纳入血脂异常干预方面内容,而是建议读者参照英国的血脂指南。在降压与抗血小板治疗方面,新版指南进行了更新。

血压管理要点如下:

1.若患者血压>140/80mmHg(合并肾脏、眼或脑血管并发症者血压>130/80mmHg),应为患者做出改善生活方式建议;

2.经生活方式干预后血压仍>140/80mmHg(合并肾脏、眼或脑血管并发症者仍>130/80mmHg),即应启动药物治疗;

3.每1-2个月监测一次血压,血压不能达标(<140/80mmHg,有肾脏[含微量白蛋白尿]、视网膜、脑并发症者<130/80mmHg)需强化治疗;

4.除非裔、加勒比裔或有妊娠可能的女性外,应首选每日一次的长效ACEI类药物;

5.不耐受ACEI治疗者(除肾功能恶化或高血钾外),选用ARB类;

6.有可能妊娠的女性首选CCB类药物;

7.经ACEI(或ARB)治疗血压不能达标者可加用CCB或噻嗪类利尿剂(优先考虑后者);仍不达标者则联合应用ACEI(或ARB)加噻嗪类利尿剂与CCB;

8.三联治疗后血压不达标者可考虑加用“a受体阻滞剂、β受体阻滞剂或保钾利尿剂;

9.血压达标后每4-6个月监测血压,确保血压持久达标。降压药物治疗过程中注意监测可能发生的不良反应,并避免血压过度降低。

在抗血小板治疗方面,该指南采取了与欧洲指南一致的立场,仅建议确诊动脉粥样硬化性心血管病的患者接受抗血小板治疗;未合并心血管病者不建议予以抗血小板药物(阿司匹林或氯吡格雷)治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-06-11 ljjj1053

    好好学习一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-04-11 x35042875

    AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-09 CRAZYDAFF

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-09 CRAZYDAFF

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-09 CRAZYDAFF

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-09 CRAZYDAFF

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-09 CRAZYDAFF

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-05 xiaoai5777

    好文章,攒

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=27138, encodeId=0b7c2e13887, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:52:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20357, encodeId=d31c2035efd, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18049, encodeId=ec4c180490f, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18050, encodeId=becf18050b3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18051, encodeId=563e18051b6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18052, encodeId=b6f61805278, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18053, encodeId=fa68180535b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CRAZYDAFF, createdTime=Mon Mar 09 22:33:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291840, encodeId=94fc1291840df, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Mar 06 09:36:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17688, encodeId=939b1e68844, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17689, encodeId=d0eb1e6896c, content=好文章,攒, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Mar 05 14:44:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-05 xiaoai5777

    好文章,攒

    0

相关资讯

Clin Oral Implants Res:2型糖尿病患者美学区种植——即刻负重亦安全

目的:本研究的目的是为了评估不同糖化血红蛋白(HbA1c)水平的糖尿病患者在接受即刻种植即刻修复后两年其种植体的存活率和初期稳定性。 材料和方法:将85例研究对象根据HbA1c的水平分为3组:第1组33例患者(HbA1c水平<6%,对照组);第2组30例患者(HbA1c水平在6.1%-8%之间);第3组22例患者(HbA1c水平在8.1%-10%之间)。每位患

JAMA:降血压治疗2型糖尿病与延长生存期相关

根据JAMA 2月10日发表的一项研究,对糖尿病患者进行降血压治疗可降低心血管疾病(CVD)、心脏病以及死亡率升高的风险。 预计到2030年,全世界将有400万人患有2型糖尿病。2型糖尿病基本上会伴随着增加心脏病和中风的风险。在糖尿病患者中血压水平平均偏高,血压增高对糖尿病患者来说是一个公认的危险因素。根据文章中的背景信息,降低糖尿病患者的血压在目前看来存在争论性的,特别是在谁应该接受治疗和要达

FDA批准2型糖尿病的新组合药片Glyxambi

美国食品药品监督管理局已经批准empagliflozin / linagliptin组合药Glyxambi(勃林格殷格翰/礼来)作为成人2型糖尿病患者饮食和锻炼的辅助治疗。 该组合药剂在美国是首个将钠葡萄糖协同转运2(SGLT2)抑制剂(empagliflozin)与二肽基酶-4(DPP-4)抑制剂(linagliptin)进行组合每日一次服用的药片。该药片包含10毫克或者25毫克的empagl

DRCP:亚洲2型糖尿病患者利拉鲁肽的药代动力学和剂量暴露反应的联系

目的:在亚洲2型糖尿病患者中,调查群体药代动力学和利拉鲁肽暴露反应的关系,利拉鲁肽——人胰高血糖素样肽-1(GLP-1)类似物。 方法:数据来源于中国,印度和韩国第16周发表的随机,双盲,双模拟,主动控制的利拉鲁肽的平行对照试验。分析利用605个每天一次暴露于利拉鲁肽0.6mg,1.2或1.8mg的患者的2061个药代动力学(PK)样品。利拉鲁肽清除率的人口因素(年龄,体重,性别,国家)的重要性

Ann Surg:非重度肥胖的2型糖尿病患者,手术治疗VS内科治疗,孰优孰劣?

肥胖手术可以实现2型糖尿病和糖尿病并发症的缓解,手术治疗一直以来也被提倡用于糖尿病合并BMI小于35kg/m的患者人群,可作为备用治疗选择。然而减重手术的有限性还没背全面系统地证实。为比较外科手术治疗和内科治疗对于BMI指数少于35kg/m的2型糖尿病患者的缓解情况和并发症发生情况,XXX的研究者进行了一项Meta分析。系统检索文献内容为评估BMI<35kg/m的糖尿病患者外科和内科治疗的随

点评:继续寻找2型糖尿病的基因是否有价值?

2型糖尿病是一种高度异质性的疾病,在复杂的基因背景下,营养物质过多摄入导致体内糖脂代谢异常,引起疾病发生。因此,遗传和环境是2型糖尿病发生的两大重要方面。正方Mark McCarthy和反方Mike Lean正是从这两个方面来看待目前关于2型糖尿病的研究。在遗传学方面,正如Mark McCarthy所说,通过GWAS研究和一些表观遗传学的研究从基础研究的角度在一定程度上揭示了基因在2型糖尿病发生中

Baidu
map
Baidu
map
Baidu
map